Citadel Advisors
BIB icon

Citadel Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Citadel Advisors’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,400
Closed -$164K – 12601
2025
Q1 		$164K Sell
3,400
-800
-19% -$42.9K ﹤0.01% 10731
2024
Q4 		$213K Buy
4,200
+1,500
+56% +$88.9K ﹤0.01% 10340
2024
Q3 		$172K Sell
2,700
-4,700
-64% -$303K ﹤0.01% 10368
2024
Q2 		$439K Buy
7,400
+2,900
+64% +$160K ﹤0.01% 8320
2024
Q1 		$259K Buy
4,500
+800
+22% +$46.4K ﹤0.01% 9785
2023
Q4 		$211K Sell
3,700
-3,800
-51% -$178K ﹤0.01% 9854
2023
Q3 		$360K Buy
7,500
+3,600
+92% +$185K ﹤0.01% 8780
2023
Q2 		$203K Sell
3,900
-2,500
-39% -$138K ﹤0.01% 9866
2023
Q1 		$347K Hold
6,400
– – ﹤0.01% 9075
2022
Q4 		$369K Sell
6,400
-700
-10% -$39.4K ﹤0.01% 8878
2022
Q3 		$338K Sell
7,100
-2,300
-24% -$123K ﹤0.01% 9306
2022
Q2 		$455K Sell
9,400
-4,900
-34% -$249K ﹤0.01% 8851
2022
Q1 		$887K Buy
14,300
+3,700
+35% +$227K ﹤0.01% 7985
2021
Q4 		$860K Buy
10,600
+3,900
+58% +$334K ﹤0.01% 8326
2021
Q3 		$636K Sell
6,700
-13,800
-67% -$1.4M ﹤0.01% 9290
2021
Q2 		$2.02M Buy
20,500
+9,600
+88% +$838K ﹤0.01% 6597
2021
Q1 		$911K Buy
10,900
+400
+4% +$37.7K ﹤0.01% 8349
2020
Q4 		$906K Sell
10,500
-4,800
-31% -$372K ﹤0.01% 7003
2020
Q3 		$1.07M Sell
15,300
-4,500
-23% -$319K ﹤0.01% 5910
2020
Q2 		$1.44M Buy
19,800
+11,000
+125% +$702K ﹤0.01% 5158
2020
Q1 		$407K Buy
8,800
+2,200
+33% +$123K ﹤0.01% 6797
2019
Q4 		$408K Sell
6,600
-5,400
-45% -$288K ﹤0.01% 7128
2019
Q3 		$510K Sell
12,000
-6,000
-33% -$284K ﹤0.01% 6708
2019
Q2 		$933K Buy
18,000
+13,500
+300% +$672K ﹤0.01% 5802
2019
Q1 		$250K Sell
4,500
-9,600
-68% -$517K ﹤0.01% 7876
2018
Q4 		$593K Buy
14,100
+2,500
+22% +$130K ﹤0.01% 6144
2018
Q3 		$808K Sell
11,600
-6,500
-36% -$425K ﹤0.01% 5911
2018
Q2 		$1.03M Sell
18,100
-4,600
-20% -$251K ﹤0.01% 5154
2018
Q1 		$1.25M Buy
22,700
+14,100
+164% +$845K ﹤0.01% 4467
2017
Q4 		$482K Sell
8,600
-3,300
-28% -$186K ﹤0.01% 5708
2017
Q3 		$729K Buy
11,900
+1,600
+16% +$91K ﹤0.01% 4786
2017
Q2 		$550K Buy
10,300
+1,000
+11% +$48.8K ﹤0.01% 4978
2017
Q1 		$449K Sell
9,300
-13,300
-59% -$618K ﹤0.01% 5205
2016
Q4 		$902K Sell
22,600
-900
-4% -$38.4K ﹤0.01% 3997
2016
Q3 		$1.14M Buy
+23,500
New +$1.12M ﹤0.01% 3667

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $236M AUM 28.3% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return

Citadel Advisors's BIB Position: Q1 2026 in Review

Citadel Advisors opened a new position in ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2026: 7,611 shares worth $620K. The stake represents ﹤0.01% of the portfolio and ranks #8770 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BIB as recently as Q3 2025.

Citadel Advisors first reported a position in BIB in Q2 2014 and has held it in 41 quarters since. The position peaked at $7.45M in Q3 2018. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

  • Citadel Advisors held 7,611 shares of ProShares Ultra NASDAQ Biotechnology worth $620K as of Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology was a new Citadel Advisors position in Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8770 holding.
  • Citadel Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2014 and has held it in 41 quarters since.
  • Citadel Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $7.45M in Q3 2018.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.